Retinoid X receptor alpha

New Scientific Evidence Emerges on How Individuals Transition From Recreational to Compulsive Use of Drugs

Retrieved on: 
Tuesday, March 7, 2023

Specifically, the nucleus accumbens is a region of the brain's reward circuitry that integrates midbrain inputs of dopamine -- a neurotransmitter that affects many aspects of behavior, including how we experience pleasure – to shape reward- and motivation-related behaviors. Within this construct, researchers in the Nash Family Department of Neuroscience and the Friedman Brain Institute at Icahn Mount Sinai learned that RXRα positively correlated with addiction-relevant behavioral features in laboratory rodents -- a finding that makes the molecule a strong mechanistic candidate to link individual vulnerability to cocaine addiction. Fundamental to the study was RNA sequencing on six regions of the rodent's brain reward circuitry after cocaine self-administration, withdrawal, and relapse in mice.

Key Points: 
  • Fundamental to the study was RNA sequencing on six regions of the rodent's brain reward circuitry after cocaine self-administration, withdrawal, and relapse in mice.
  • The discovery not only paves the way for future research on the novel signaling pathway, but on preventive strategies for drug addiction targeting RXRα.
  • The Mount Sinai team showed that inhibition of the molecule using a systemically administered RXRα antagonist reduced cocaine-induced associative learning with tolerable side effects.
  • Scientists were particularly intrigued and encouraged by the fact that a single molecule could have such a profound effect on modulating complex behaviors related to drug addiction.

Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium

Retrieved on: 
Friday, October 28, 2022

Stratification of patients based upon their PPARG status serves as the foundation for our precision approach in identifying individuals most likely to respond to PPARG inhibition.

Key Points: 
  • Stratification of patients based upon their PPARG status serves as the foundation for our precision approach in identifying individuals most likely to respond to PPARG inhibition.
  • This disease has high rates of recurrence and the five-year survival rate is approximately 5% in metastatic cases.
  • The transcription factor peroxisome proliferator-activated receptor gamma (PPARG) is associated with the luminal lineage subtype reflecting approximately 65% of all advanced UC patients.
  • Flare Therapeutics is a biotechnology company pioneering a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.

Flare Therapeutics Presents Preclinical Data that Show Potential of Novel PPARG Inhibitors to Treat Urothelial Cancer at 2022 EORTC-NCI-AACR Symposium

Retrieved on: 
Wednesday, October 26, 2022

Our goal is to add PPARG to that list, to potentially enable treatment of urothelial cancers.

Key Points: 
  • Our goal is to add PPARG to that list, to potentially enable treatment of urothelial cancers.
  • In preclinical models, FTX-6746 demonstrated a favorable therapeutic profile, suppressing PPARG target genes with durable tumor regression at well-tolerated doses.
  • Flare is poised to transition to a clinical-stage company early next year with our lead molecule in the PPARG program.
  • Flare Therapeutics is a biotechnology company pioneering a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.

Pipeline Review for Retinoic Acid Receptor Gamma, H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 19, 2020

The "Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020'; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 17 molecules.
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene.
  • The report 'Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020' outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.